Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116495782 | 11649578 | 2 | F | 20160714 | 20151021 | 20160715 | EXP | TW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-068942 | BRISTOL MYERS SQUIBB | 39.00 | YR | F | Y | 0.00000 | 20160715 | OT | TW | TW |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116495782 | 11649578 | 1 | PS | ARIPIPRAZOLE. | ARIPIPRAZOLE | 1 | Oral | 20 MG, QD | 21436 | 20 | MG | QD | |||||||
| 116495782 | 11649578 | 2 | SS | ARIPIPRAZOLE. | ARIPIPRAZOLE | 1 | Oral | 30 MG, QD | 21436 | 30 | MG | QD | |||||||
| 116495782 | 11649578 | 3 | SS | ARIPIPRAZOLE. | ARIPIPRAZOLE | 1 | 21436 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 116495782 | 11649578 | 1 | Hyperprolactinaemia |
| 116495782 | 11649578 | 2 | Delusion |
| 116495782 | 11649578 | 3 | Schizophrenia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 116495782 | 11649578 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 116495782 | 11649578 | Off label use | |
| 116495782 | 11649578 | Psychotic disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |